Overview

Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer

Status:
RECRUITING

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU/LV in perioperative treatment of borderline resectable pancreatic cancer in 45 patients.

Phase:

PHASE2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Oxaliplatin
Surgical Procedures, Operative